mismatched donors. Tacrolimus and mycophenolate mofetil were administered after HSCT. See Table 1 for details.
CMV DNAemia was determined by a quantitative realtime PCR from whole blood sampled in tubes with EDTA. DNA extraction was performed using QIAamp DNA Mini Kit (Qiagen, Hilden, Germany), quantitative DNA detection by Artus CMV RG PCR KIT [96] CE (Qiagen) on the thermocycler CMV Rotor-Gene (RG) (Qiagen). The limit of detection was 100 copies of CMV DNA per milliliter (cp/ml, equivalent of 79.4 IU/ml) and the limit of quantification was 500 cp/ml of the assay. CMV DNAemia was monitored weekly until day 100 for patients with uncomplicated clinical statuses, surveillance then continued every 2-3 weeks. UL97 (codons 460-607) and UL54 gene (codons 408-987) analysis was performed retrospectively using Sequencer Applied Biosystems 3130/3130 × (Applied Biosystems, Waltham, MA, USA) [4] from frozen positive samples taken at the time of treatment failure diagnosis (at least 2 weeks of antiviral therapy (range 15-33 days)) to determine mutation development date (8-14 samples per patient). For patients with treatment failure we analyzed 2-3 samples per patient with median of 11 400 cp/ml (range, 3370-1,130,000), two of these samples were taken when the DNAemia was at peak level. The results were compared with reference strain AD169, GenBank No FJ527563.1. A tool for locating changes in UL97/UL54 genes from reference AD169 strain was created (a trial version available at https://www.vejrazka.name/apps/med/ dna/sample_matching/, without any availability guarantees, Aug 1, 2016) . Results were compared to previously published polymorphism and mutation data as well as the German program for CMV mutation detection [3] . CMV replication was considered if the viral load was above 100 cp/ml. Preemptive treatment using valganciclovir (VGCV) was started for viral loads above 1000 cp/ml. VGCV doses were 900 mg BID until viral load reduced to 50%. VGCV was then administered once a day for at least 2 weeks (maintenance therapy) until DNAemia was negative. Maintenance therapy was not initiated or was limited to 1 week if the initial viral load was lower than 10 4 cp/ml and DNAemia became negative during the initial therapy. Ganciclovir (GCV, intravenous only) or forcarnet (FOS) treatment schema were used for CMV disease according to the NCCN Guidelines [5] . Categorical data were analyzed using the Fisher exact test for 2 × 2 contingency table. Non-parametric Mann-Whitney test was used for comparing independent groups. P-values ≤ 0.05 were considered statistically significant.
CMV replications were detected in 72 patients (69%) of which 58 were treated for it. Treatment failure was observed in seven patients (12%) during the anti-CMV UL97 therapy. Three cases of CMV UL97 mutation coding resistance (L595F, M460I, A594V) were detected-see Table 2 for clinical data. These codons had been referred to in the literature as mutation sites leading to GCV resistance [6] .
The median time to treatment failure diagnosis was 118 days after HSCT (range: 48-168). It was 168 days for the three patients with resistant mutation (median of 90 days of cumulative treatment). The four patients without detected mutation had the median time to clinical resistance 62 days (median of 18.5 days of cumulative VGCV/GCV treatment, p = 0.0497).
Patients with treatment failure were treated for longer cumulative time during the first post-HSCT year compared to the patients responding to therapy (median of 97 vs. 39 days, p = 0.0035), had a higher viral load peak (median of 41,500 vs. 4160 cp/ml, p = 0.0003), and the viral load at the start of maintenance therapy was also higher (median of 1305 vs. 437 cp/ml, p = 0.0173). There were no differences between times to the first CMV reactivation or treatment onset between these patient groups (median of 34 vs. 27 days, p = 0.13; resp. 31 vs. 42 days, p = 0.08). The initial CMV DNA load was also comparable (1700 cp/ml for patients with treatment failure vs. 455 cp/ml, p = 0.073).
Positive There were no significant differences between patients responding to antiviral therapy and patients with treatment failure in the following factors: patients' age or Karnofsky score at time of HSCT, CD34 + cell dose in HSCT graft, achieving complete remission before HSCT, fully HLA HSCT hematopoietic stem cell transplantation a Including the three re-transplantations matched donor vs. mismatched donor, regimen using thymoglobulin, regimen using TBI, myeloablative vs. reducedintensity conditioning, GVHD incidence, necessity of GVHD corticosteroid treatment, achieving complete donor chimerism after HSCT, relapse incidence (p = 0.147-1.0). No significant differences in these factors were also found between patients with proven CMV resistance and other treated patients (p = 0.141-1.0). CMV disease [7] was observed in eight patients. One case of CMV retinitis (day 266 after HSCT), six cases of early CMV enterocolitis (range: day 29-98), and three cases of late CMV colitis (range: day 132-346) were observed. CMV disease occurred more often in patients with treatment failure; (p = 0.047) and viral resistance (p = 0.04) than in the rest of the group.
The incidence of viral resistance was 5% in patients treated using antiviral therapy, matching published results [8, 9] . A single case of UL97 N510S change (with no other polymorphism or deletion) was detected. This patient had recurrent CMV reactivations. This polymorphism had initially been suspected to be linked to a ganciclovir resistance [10] , but no significant resistance was confirmed by recombinant phenotyping [11] .
The median time of treatment failure diagnosis in patients with viral resistance was 168 days, which is slightly more than in Boutolleau's cohort [12] , Shmueli [8] describes a shorter time. Differences might be explained by heterogeneity of patient's cohorts (different types of HSCTs and solid organ transplant recipients and schemes of anti-CMV prophylaxis/ treatment). A alanine, AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, Bu busulfan, CLL chronic lymphocytic leukemia, CMV human cytomegalovirus, cp/ml copies of CMV DNA per milliliter, D-/R + -CMV seronegative donor/seropositive recipient, F phenylalanine, Flu fludarabine, GCV ganciclovir, GVHD graft vs. host disease, HSCT hematopoietic stem cell transplantation, I isoleucine, L leucine, M methionine, MMUD mismatched unrelated donor, MUD matched unrelated donor, TBI total body irradiation, Tg thymoglobulin, Treo treosulfan, V valine, VGCV valganciclovir a First of 3 consecutive days with the indicated blood cell level, no transfusions for at least 7 days before reconstitution [14] Patients with treatment failure were treated for a longer cumulative time and had a higher viral load peak compared to the patients responding to antiviral therapy, matching others' results [8, 12] .
Guidelines recommend administering induction doses for at least 2 weeks until tests are negative [5] ; nevertheless no randomized trial of maintenance therapy for HSCT recipients is available [13] . Boutolleau et al. [12] reported that the start of valganciclovir maintenance treatment while CMV DNA is still detectable in peripheral blood might represent a risk factor for the CMV resistance. The VGCV maintenance therapy in 23 of our patients whose clinical status was good was started only when DNAemia decreased by at least 50% (the median of viral load was 613 cp/ml), to work around potential VGCV myelotoxicity and nephrotoxicity. There was a significant difference in detectable viral loads between the patients with treatment failure and the patients responding to antiviral therapy at the time of maintenance therapy onset (median of 1305 vs. 437 cp/ml, p = 0.0173). We did not observe this in the group of patients with viral strain resistance mutation (1420 cp/ml) vs. other treated patients (495 cp/ml, p = 0.11).
We were unable to confirm statistical significance of serostatus for CMV resistance unlike other published works [1, 8] . This was likely due to the size of our cohort.
Data on ganciclovir levels were not available. Phenotypic methods are not available in the Czech Republic, the Sanger sequencing was aiming only at sections of UL97 and UL54 most frequently associated with resistance, new rare mutations might have been missed.
The weakness of our study is that results are based on only few patients with CMV resistance due to its low incidence. The results confirm and enhance current knowledge of CMV resistance in HSCT recipients.
Our data indicate that only a portion of treatment failure cases are linked to proven viral resistant mutations. Patients with prolonged antiviral therapy and high viral load should be monitored closely, testing of viral susceptibility should be performed when the response to antiviral therapy is not satisfactory. 
